AC Immune develops treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, based in Lausanne, Switzerland. ACIU reports earnings on Tue, Nov 3, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 20 | BTIG | Reiterated | Buy |
Seasonality
How ACIU has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in ACIU in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACIU is in one of them and how their past ACIU trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACIU in an article yet. Here's the latest on the wider market.
About AC Immune SA
AC Immune is a biopharmaceutical company based in Lausanne, Switzerland, that develops treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its candidates include active immunotherapies, which are biologic treatments, and small molecule drugs designed to act inside brain cells. The company uses its own technology platforms to design these candidates and has partnered with large global pharmaceutical companies on parts of its pipeline.
- Headquarters
- 1015 Lausanne, Switzerland